Skip to content
Studies have shown that active fund managers routinely underperform the S&P500 index*
Home
Articles
WALL STREET X
Forecasts
Portfolios
Wall Street X
Articles
Forecasts
Portfolios
Search
Results for
{phrase}
(
{results_count}
of
{results_count_total}
)
Displaying
{results_count}
results of
{results_count_total}
Seres Therapeutics, Inc. (NASDAQ: MCRB)
MCRB Stock Predictions and Ratings
WSX Rating:
STRONG SELL
WSX Forecast (1yr):
-16.90%
Analyst Rating:
STRONG BUY
Analyst Forecast (1yr):
53.40%
MCRB Stock Analysis
MCRB
PE Ratio:
MCRB
PEG Ratio:
Not Available
MCRB
Forward EPS Growth (12 month):
0.00%
MCRB
PS Ratio:
60.7
MCRB
PSG Ratio:
Not Available
MCRB
Forward Revenue Growth (12 month):
0.00%
MCRB Articles
No data was found